Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement to develop and commercialize seralutinib.
This global collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate the development of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
“Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD, and we could not be more excited to partner with Gossamer to develop and bring this therapy to patients worldwide,” said Giuseppe Accogli, Group CEO of Chiesi.
PAH is believed to affect approximately 30,000 to 50,000 people in the US, with a similar prevalence in Europe. While many approved PAH treatments ...
Full story available on Benzinga.com